Scheibler Lukas's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Apr 6, 2022
- Accession no.
- 0001127602-22-011670
- Filed
- Apr 6, 2022
- Trade date
- Apr 5, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $36.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Scheibler LukasCIK 0001651281 | Officer (CHIEF INNOVATION OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 5, 2022 | Common Stock | MOption exerciseAcquired | +609 | $13.85 | +$8,434.65 | 52,842 | Direct | |
| Apr 5, 2022 | Common Stock | SSaleDisposed | −609 | $60.09 | −$36,594.81 | 52,233 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 5, 2022 | Common Stock | MOption exerciseDisposed | −609 | $0.00 | $0 | 49,391 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.